Journals / Experimental Biomedical Research / 2021 / Cilt: 4 - Sayı: 4

COVID-19 and comorbidities: Predictors, clinical course, relationship with disease severity, and outcome

Pages
302–313
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: In this study, we found that the presence of comorbidity did not affect mortality and duration of stay and that the severity of radiological involvement, the severity of hypoxemia, and the increase in inflammation markers were the determinants of mortality.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: COVID-19 disease has a broad spectrum ranging from asymptomatic course to death.
📊
Key Findings & Data:This study aimed to investigate the effect of comorbidity on the clinical course and mortality of COVID-19 pneumonia.
💡
Conclusion & Impact:Conclusions: In this study, we found that the presence of comorbidity did not affect mortality and duration of stay and that the severity of radiological involvement, the severity of hypoxemia, and the increase in inflammation markers were the determinants of mortality.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Özet

Aim: COVID-19 disease has a broad spectrum ranging from asymptomatic course to death. While data show that the prognosis of the disease will be poor in the presence of comorbidity, we witness the death of patients with no comorbidities in our clinical practice. This study aimed to investigate the effect of comorbidity on the clinical course and mortality of COVID-19 pneumonia. Methods: 155 Rt-PCR (+) adult patients hospitalized at İzzet Baysal State Hospital (Bolu, Turkey) diagnosed with severe and critical pneumonia between August 2020 and February 2021 were included in this single center, retrospective study. The patients were divided into two groups with and without comorbidity, compared the severity of inflammation parameters, radiological involvement, and oxygen requirement, and evaluated their effects on mortality and hospitalization duration. Results: There was no significant difference in the severity of the computed tomography (CT) involvement, the oxygen requirement, inflammation markers, and duration of hospitalization in patients with comorbidities compared to those without. When we evaluated the patients with comorbidities in general and their subgroups, the relationship with mortality was not significant. The severity of CT involvement, high oxygen requirement, and inflammation markers such as lymphocyte, lymphocyte ratio, LDH, CRP, troponin, ferritin levels were found to be associated with mortality. Conclusions: In this study, we found that the presence of comorbidity did not affect mortality and duration of stay and that the severity of radiological involvement, the severity of hypoxemia, and the increase in inflammation markers were the determinants of mortality.

🔖

Cite This Article

AFŞİN, E., COŞGUN, M. (2021). COVID-19 and comorbidities: Predictors, clinical course, relationship with disease severity, and outcome. Experimental Biomedical Research, Cilt: 4 - Sayı: 4, 302–313. https://ajindex.com/articles/407201

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Anca PS, Toth PP, Kempler P, et al. Gender differences in the battle against COVID-19: Impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes. Int J Clin Pract. 2021;75(2):e13666. [2]Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. [3]Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782-92. [4]Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One. 2020;15(5):e0233147. [5]Jarahzadeh MH, Asadian F, Farbod M, et al. Cancer and Coronavirus Disease (COVID19): Comorbidity, Mechanical Ventilation, and Death Risk. J Gastrointest Cancer. 2021;52(1):80-84. [6][6] World Health Organization, et al. Clinical management of severe acute respiratory infection ( SARI) when COVID19 disease is suspected: interim guidance, 13 March 2020. World Health Organization, 2020. [7]Li L, Huang T, Wang Y, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92 (6):1–7. [8]Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. [9]Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019
  2. Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. [10]Ucan ES, Ozgen Alpaydin A, et al. DEU COVID Study Group. Pneumonia severity indices predict prognosis in coronavirus disease-2019. Respir Med Res. 2021;79:100826. [11]Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605- 10. [12]Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28(1):15- 21. [13]Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential ap